Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14-21
SponsorUniversity of California, Los Angeles

About this trial

Despite the prevalence and significant public health concern over depression among adolescents, up to 40% of depressed adolescents do not respond to first-line antidepressants (herein termed treatment non-response, TNR). The goal of this project is to recruit and assess 160 treatment-seeking depressed adolescents and test whether acute stress impacts peripheral levels of inflammation and downstream levels of glutamate in corticolimbic regions previously associated with depression, whether these stress-related biomarkers predict TNR to a 12-week trial of either fluoxetine or escitalopram, and whether these stress-related biomarkers predict 18-month clinical course.

Eligibility criteria

Qualifiers

All sexes and genders

All ethnicities

Ages 14-21

Postpubertal (Tanner stage > 3)

Disqualifiers

Primary mental health diagnosis other than a depressive disorder according to DSM-V

Any contraindications to MRI scanning, phlebotomy, or SSRI treatment

Stimulant usage

A concussion within the last 6 weeks or any lifetime concussion with loss of consciousness for at least 10 minutes

Trial design

Treatments tested in this trial

  • Trier Social Stress Test (TSST)

Treatment groups

160 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of California, Los Angeles

Lead sponsor

University of Southern California

Collaborator

University of California, Irvine

Collaborator

Columbia University

Collaborator

Mayo Clinic

Collaborator

University of California, San Francisco

Collaborator

National Institute of Mental Health (NIMH)

Collaborator